The FDA has warned about Glyxambi adverse effects and other side effects from a number of similar type-2 diabetes medications, noting that they may increase the risk of ketoacidosis and kidney failure, among other problems.

If you or someone you love was diagnosed with ketoacidosis, kidney failure, or other Glyxambi adverse effects after taking the diabetes medication, you may be able to file a Glyxambi lawsuit.

Glyxambi Background

Glyxambi (empagliflozin linagliptin) is a type-2 diabetes medication. Glyxambi is used to help control a diabetes patient’s blood sugar levels. Empagliflozin, the first component of Glyxambi, helps the kidneys rid the bloodstream of glucose. The second component, linagliptin, regulates the body’s levels of insulin after the patient eats.

Glyxambi was approved as a type-2 diabetes treatment by the FDA in January 2015. Glyxambi is manufactured by Boehringer Ingelheim and Eli Lilly, who individually manufacture its components under the trade names Jardinace and Tradjenta.

Glyxambi, as the combination of these two medications, is becoming an increasingly popular choice for patients with type-2 diabetes.

FDA Warning

The U.S. Food and Drug Administration (FDA) issued a warning about these type-2 diabetes medications on May 15, 2015. According to the FDA, diabetes drugs like Glyxambi can cause a range of severe Glyxambi adverse effects, including ketoacidosis and kidney failure.

The FDA’s Adverse Event Reporting System (FAERS) began receiving reports of diabetic ketoacidosis and ketosis in patients who received treatment from SGLT2 inhibitor medications when the drugs were just entering the market. FAERS showed 20 cases of these adverse effects linked with SGLT2 inhibitors between March 2013 and June 2014, all of which involved cases serious enough for hospitalization or visits to the emergency room.

As time goes by, the FDA has received more and more reports of adverse effects to these type-2 diabetes medications.

Diabetes medications included in the FDA warning are those belonging to a class of drugs known as sodium glucose contransporter-2 (SGLT2) inhibitors. This class includes the following medications:

• Glyxambi (empagliflozin linagliptin)
• Invokana (canagliflozin)
• Invokamet (canagliflozin metformin)
• Jardiance (empagliflozin)
• Xigduo XR (dapagliflozin metformin)
• Farxiga (dapagliflozin)

The FDA warned patients to be on the lookout for symptoms of serious adverse effects from these SGLT2 drugs, including:

• Difficulty breathing
• Abdominal pain
• Nausea
• Vomiting
• Confusion
• Unusual levels of fatigue or depression

Potential Glyxambi adverse effects also include pancreatitis, or inflammation of the pancreas, a condition that can be severe and, in some cases, even fatal; ketoacidosis, which requires hospitalization; kidney failure or disease; and dehydration.

Filing a Lawsuit Over Glyxambi Adverse Effects

If you or someone you love has suffered from Glyxambi adverse effects like ketoacidosis after taking the type-2 diabetes drug, you may be in a position to file a Glyxambi lawsuit.

Filing a legal claim cannot take away the pain and suffering of Glyxambi adverse effects, but it can help to alleviate the financial costs of medical expenses and even lost wages.